Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- 21:00 - 23:59
- 8/06/2022
- Location: On-Demand
- Not for CME Credit
- Type: Workshop
- Track: N/A
- Moderators:Yi-Long Wu, Chunxue Bai, Caicun Zhou, Karen Kelly
-
+
Session Moderator
21:00 - 21:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
Session Moderator
21:00 - 21:00 | Presenter: Chunxue Bai
- Abstract
Loading... -
+
Session Moderator
21:00 - 21:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
Session Moderator
21:00 - 21:00 | Presenter: Karen Kelly
- Abstract
Loading... -
+
WS08.01 - Session Introduction
21:00 - 21:02 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
WS08.02 - Session Introduction
21:02 - 21:04 | Presenter: Chunxue Bai
- Abstract
Loading... -
+
WS08.03 - Session Introduction
21:04 - 21:07 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
WS08.04 - Session Introduction
21:07 - 21:10 | Presenter: Karen Kelly
- Abstract
Loading... -
+
WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective
21:10 - 21:30 | Presenter: Jia-Tao Zhang
- Abstract
Loading... -
+
WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective
21:30 - 21:50 | Presenter: Aadel Chaudhuri
- Abstract
Loading... -
+
WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC
21:50 - 22:10 | Presenter: Jie Hu
- Abstract
Loading... -
+
WS08.08 - Liquid Biopsy for Advanced Oncogene Driven NSCLC. European Perspective
22:10 - 22:30 | Presenter: Martin Filipits
- Abstract
Loading... -
+
WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
22:30 - 22:40 | Presenter: Si-Yang Maggie Liu
- Abstract
Loading... -
+
WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
22:40 - 22:50 | Presenter: Xuxinyi Ling
- Abstract
Loading... -
+
WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
22:50 - 23:00 | Presenter: Yun Fan
- Abstract
This abstract is currently under embargo and will be released during the conference.
-
+
WS08.12 - Discussant for Oral Abstracts
23:00 - 23:20 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading... -
+
WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial
23:20 - 23:21 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
23:21 - 23:22 | Presenter: Lin Wu
- Abstract
Loading... -
+
WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
23:22 - 23:23 | Presenter: Jun Zhao
- Abstract
Loading... -
+
WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
23:23 - 23:24 | Presenter: Juan Zhou
- Abstract
Loading... -
+
WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
23:24 - 23:25 | Presenter: Wenbin Li
- Abstract
Loading... -
+
WS08.18 - Discussant for Poster 1 - 5
23:25 - 23:40 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
23:40 - 23:41 | Presenter: Yao-Bin Lin
- Abstract
Loading... -
+
WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
23:41 - 23:42 | Presenter: Yuan Li
- Abstract
Loading... -
+
WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
23:42 - 23:43 | Presenter: Wen-Fang Tang
- Abstract
Loading... -
+
WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)
23:43 - 23:44 | Presenter: Shi Yan
- Abstract
Loading... -
+
WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
23:44 - 23:45 | Presenter: Shun Lu
- Abstract
Loading... -
+
WS08.24 - Discussant for Poster 6 - 10
23:35 - 23:50 | Presenter: Ming Fang Zhao
- Abstract
Loading...
-
+
MA02 - Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics
- 10:45 - 11:45
- 8/07/2022
- Location: Hall C8
- Not for CME Credit
- Type: Mini Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Erik Thunnissen, Rafael Rosell
-
+
MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
10:57 - 11:02 | Presenter: Jie Huang
- Abstract
Loading...
-
+
OA02 - From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment
- 12:00 - 13:00
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Locally Advanced Non-small Cell Lung Cancer
- Moderators:Isabelle Opitz, Luis Paz-Ares
-
+
OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
12:22 - 12:32 | Presenter: Yi-Long Wu
- Abstract
Loading...
-
+
OA03 - Molecular Targeted Treatments
- 14:30 - 15:40
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Andrew Ciupek, David R. Gandara
-
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Presenter: Michael Thomas
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Presenter: Jun Zhao- Abstract
Loading... -
+
EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Presenter: Jun Zhao- Abstract
Loading... -
+
EP08.01-085 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Presenter: Si-Yang Maggie Liu- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
Presenter: Frans Opdam- Abstract
Loading... -
+
EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Presenter: Qing Zhou- Abstract
Loading... -
+
EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Presenter: Qing Zhou- Abstract
Loading... -
+
EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Presenter: Marina Chiara Garassino- Abstract
Loading...
-
+
EP10.01 - Palliative and Supportive Care
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Palliative and Supportive Care
-
+
EP10.01-010 - Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)
Presenter: ZHEN WANG- Abstract
Loading...
-
+
EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
-
+
EP16.01-025 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Presenter: Wen-Fang Tang- Abstract
Loading...
-
+
EP16.02 - Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
-
+
EP16.02-024 - Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer
Presenter: Rui Fu- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
15:02 - 15:12 | Presenter: Delvys Rodriguez-Abreu
- Abstract
Loading...
